(redirected from ATryn)
Also found in: Dictionary, Encyclopedia.


any naturally occurring or therapeutically administered substance that neutralizes the action of thrombin and thus limits or restricts blood coagulation.
antithrombin I fibrin, referring to the capacity of fibrin to adsorb thrombin and thus neutralize it.
antithrombin III a naturally occurring inhibitor of blood coagulation; it is an α2-globulin member of the serpin group, synthesized in the liver and found in the plasma and various extravascular sites. It inactivates thrombin as well as certain coagulation factors and kallikrein. Inherited deficiency of the protein, an autosomal dominant disorder, is associated with recurrent deep vein thrombosis and pulmonary emboli. Complications from the disorder are prevented and, in conjunction with heparin, treated with a preparation of antithrombin III from pooled human plasma, administered intravenously.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.


Any substance that inhibits or prevents the effects of thrombin in such a manner that blood does not coagulate. A deficiency of antithrombin results in impaired inhibition of coagulation factors IIa, IXa, and Xa in plasma, causing recurrent thrombosis.
Farlex Partner Medical Dictionary © Farlex 2012


A plasma protein that diminishes the activity of THROMBIN, or the amount of thrombin produced during or following coagulation of the blood.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005


Any substance that counters the effect of thrombin, an enzyme that converts fibrinogen into fibrin, leading to blood coagulation.
Gale Encyclopedia of Medicine. Copyright 2008 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
ATryn is the first transgenically produced therapeutic protein and the first recombinant antithrombin approved in the United States.
The company laid off one-third of its workforce in November 2009 and winnowed its work down to ATryn and a second program with LFB Biotechnologies of France to produce recombinant Factor VIIa, a blood protein for the treatment of hemophilia.
LEO previously had an agreement to commercialize ATryn, a GTC product that regulates blood clotting, in Canada, Europe and the Middle East.
commercial rights to its anti-clotting drug ATryn from Danish company H.
GTC reported it will focus on getting its Factor VIIa program into human studies, improving the financial performance of its blood treatment ATryn and using its technology to advance possible protein therapeutics, especially in the area of "bio-similar," or generic, biotech treatments.
ATryn, GTC's recombinant human antithrombin, has been approved for use in the United States and Europe.
Bio Sidus will cover the costs of obtaining sales authorizations for ATryn, a treatment for blood clotting that is based on a compound drawn from the milk of genetically altered goats.
The job cuts and a decision to focus work on ATryn and Factor VIIa programs should save $5 million to $6 million in annualized expenses, the company reported.
The company said it will reduce expenses, saving $5 million to $6 million in 2010 by focusing on its ATryn and blood factor VIIa programs.
FRAMINGHAM - ATryn, the first approved drug made in the milk of genetically altered animals, has gone on sale in the United States, GTC Biotherapeutics Inc.
Lundbeck A/S, as a result of the approval of ATryn by the U.S.
has notified LEO Pharma A/S that GTC is terminating its contract for commercialization and development of ATryn, GTC's recombinant form of human antithrombin, in Europe, Canada and the Middle East.